Company / EPS (Diluted)
PTC Therapeutics, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$8.37
FY2025
5-year range
-$8.37 / -$4.27
FY2021-FY2025
Trend
-7.4%
vs FY2024
Sector context
#195 of 204
Health Care
What the data says
Among 204 Health Care companies, PTC Therapeutics, Inc. is in the bottom 4% for eps (diluted). EPS (Diluted) has declined for 5 consecutive years, from $-2.75 in FY2020 to $-8.37 in FY2025.
Based on SEC 10-K filings.
-8.37 in FY2025.
Declined from $-7.43 to $-8.37 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 204This company -$8.37 Sector average -$0.98
▼
-754.4% below sector average
Key checks
Key Insights
- PTC Therapeutics, Inc.'s eps (diluted) has declined for 5 consecutive years.
- In FY2025, eps (diluted) decreased 7.4% year-over-year.
- Ranks #195 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$8.37 | -7.4% |
| FY2024 | -$7.79 | -4.8% |
| FY2023 | -$7.43 | -11.9% |
| FY2022 | -$6.64 | -55.5% |
| FY2021 | -$4.27 | -55.3% |
| FY2020 | -$2.75 | +35.6% |
| FY2019 | -$4.27 | -2.4% |
| FY2018 | -$4.17 | +17.8% |
| FY2017 | -$5.07 | -70.7% |
| FY2016 | -$2.97 | +42.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026